Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
6. Netzwerktreffen der zertifizierten Hautkrebszentren.
Utikal J, Huber M, Meier F, Meiß F, Weichenthal M, Schneider LA. Utikal J, et al. J Dtsch Dermatol Ges. 2020 Jul;18(7):783-784. doi: 10.1111/ddg.14129_g. J Dtsch Dermatol Ges. 2020. PMID: 32713139 German. No abstract available.
[First network meeting of the certified skin tumor centers].
Eigentler TK, Utikal J, Huber MA, Meiss F, Schneider LA. Eigentler TK, et al. Among authors: utikal j. J Dtsch Dermatol Ges. 2015 Aug;13(8):847-8. doi: 10.1111/ddg.12762. J Dtsch Dermatol Ges. 2015. PMID: 26213830 German. No abstract available.
Zweites Netzwerktreffen der zertifizierten Hauttumorzentren.
Utikal J, Eigentler TK, Huber MA, Meiss F, Weichenthal M, Schneider LA. Utikal J, et al. J Dtsch Dermatol Ges. 2016 Oct;14(10):1051-1052. doi: 10.1111/ddg.13149. J Dtsch Dermatol Ges. 2016. PMID: 27767267 No abstract available.
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study.
Tietze JK, Forschner A, Loquai C, Mitzel-Rink H, Zimmer L, Meiss F, Rafei-Shamsabadi D, Utikal J, Bergmann M, Meier F, Kreuzberg N, Schlaak M, Weishaupt C, Pföhler C, Ziemer M, Fluck M, Rainer J, Heppt MV, Berking C. Tietze JK, et al. Among authors: utikal j. Oncotarget. 2018 Sep 28;9(76):34336-34346. doi: 10.18632/oncotarget.26149. eCollection 2018 Sep 28. Oncotarget. 2018. PMID: 30344946 Free PMC article.
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F. Rauschenberg R, et al. Among authors: utikal j. Eur J Cancer. 2019 Mar;110:11-20. doi: 10.1016/j.ejca.2018.12.023. Epub 2019 Feb 7. Eur J Cancer. 2019. PMID: 30739835 Free article.
5. Netzwerktreffen der zertifizierten Hautkrebszentren.
Utikal J, Eigentler T, Huber MA, Meiß F, Schneider LA, Weichenthal M. Utikal J, et al. J Dtsch Dermatol Ges. 2019 Jul;17(7):763-764. doi: 10.1111/ddg.13873. J Dtsch Dermatol Ges. 2019. PMID: 31364288 No abstract available.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group. Eggermont AMM, et al. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Bottomley A, et al. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A, Philip M, Hassel JC, Glutsch V, Fiocco Z, Loquai C, Rafei-Shamsabadi D, Gutzmer R, Utikal J, Haferkamp S, Reinhardt L, Kähler KC, Weishaupt C, Moreira A, Thoms KM, Wilhelm T, Pföhler C, Roesch A, Ugurel S, Zimmer L, Stadtler N, Sucker A, Kiecker F, Heinzerling L, Meier F, Meiss F, Schlaak M, Schilling B, Horn S, Schadendorf D, Livingstone E. Zaremba A, et al. Among authors: utikal j. Eur J Cancer. 2021 Jul;152:139-154. doi: 10.1016/j.ejca.2021.04.032. Epub 2021 Jun 5. Eur J Cancer. 2021. PMID: 34102453
345 results